Grants and Contributions:
Title:
Development and candidate selection for amyloid-depleting antibodies for the treatment light chain and ALECT2 amyloidosis
Agreement Number:
1003392
Agreement Value:
$183,595.00
Agreement Date:
Jan 11, 2023 - Apr 30, 2024
Description:
Identification, characterization, and screening of monoclonal antibodies for the treatment of ? and ?-light chain amyloidosis and drug discovery for ALECT2 amyloidosis. Potential candidates will be screened for in vitro binding affinity and specificity and for in vivo activity in cell and small animal models.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Toronto, Ontario, CA M5G 0B7
Reference Number:
172-2022-2023-Q4-1003392
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
758832877
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 2 time(s). The end date of this agreements has been modified by 152 days. The total amended value is -11,905 dollars.
Amendment Date
Nov 28, 2023
Recipient's Legal Name:
Paradox Immunotherapeutics Incorporated
Federal Riding Name:
University--Rosedale
Federal Riding Number:
35110
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
54171
Amendments: